Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors

You must be a registrant of the European Society of Gynaecological Oncology (ESGO) State of the Art Conference 2020 Virtual Meeting in order to access this event.

Join us for this dynamic, IME live Webinar where ovarian cancer experts will provide a global view on PARP inhibitors and biomarker-driven treatment strategies in ovarian cancer; including patient case discussions and discussion of new data.

Thank you for your interest in attending the Clinical Care Options (CCO) live Webinar, “Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors.”

This live Webinar will feature expert faculty, and provide interactivity, evidence-based content, and panel discussions. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services

Please note, this internationally focused program is intended for gynecologic oncologists, medical oncologists, and other healthcare providers with a primary practice outside of the United States.

Agenda

  • Consideration of patient-specific and disease-specific factors that influence the prioritization of different PARP inhibitors
  • Comparison of pharmacologic properties of approved and investigational PARPi
  • Role of PARPi maintenance therapy in newly diagnosed ovarian cancer
  • Genetic drivers of ovarian cancer development
  • PARP inhibitor-related adverse event identification and management
  • Future directions for PARPi therapy in frontline ovarian cancer

Faculty

Program Director
Ursula Matulonis, MD

Medical Director & Program Leader
Gynecologic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Faculty
Antonio González-Martín, MD, PhD

Head, Medical Oncology
Co-Director, Oncology Department
Oncology Department, Medical Oncology Service
Clinica Universidad Navarra
Madrid, Spain

Faculty
Ignace Vergote, MD, PhD

Professor of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven, Belgium

This educational activity is not certified for CME/CE credit.

Goal Statement
The goal of this activity is to improve global learners’ knowledge and competence in applying practice-changing clinical data and expert recommendations to optimize the use of PARP inhibitors for the treatment of patients with ovarian cancer.

Target Audience
This program is intended for global gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess the improvement in risk of progression from the addition of PARP inhibitors in frontline treatment and how maintenance therapy can affect this improvement
  • Discuss patient and tumor characteristics that identify candidates for treatment with frontline PARP inhibitors
  • Describe the differences among the PARP inhibitors regarding dosing, administration, adverse events, and overall properties

Accreditation

This educational activity is not certified for CME/CE credit.